| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/30/2009 | US20090192088 Vascular Endothelial Growth Factor 2 |
| 07/30/2009 | US20090192078 Methods for diagnosis of cardiovascular disease |
| 07/30/2009 | US20090191640 Methods of Screening for Atherosclerosis |
| 07/30/2009 | US20090191572 Imaging, diagnosis and treatment of disease |
| 07/30/2009 | US20090191253 Use of K-252a and Kinase Inhibitors for the Prevention or Treatment of HMGB1-Associated Pathologies |
| 07/30/2009 | US20090191244 Microbubbles and methods for oxygen delivery |
| 07/30/2009 | US20090191212 Heavy chain fragments, light chain fragments, and CDRs of fully human antibodies, that bind to angiopoietin-2; inhibits undesired angiogenesis |
| 07/30/2009 | US20090191177 Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 |
| 07/30/2009 | US20090191173 Induction Of Neurogenesis And Stem Cell Therapy In Combination With Copolymer 1 |
| 07/30/2009 | US20090191165 Fibrin glue composition for repairing nerve damage and methods thereof |
| 07/30/2009 | US20090191146 Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 07/30/2009 | US20090191117 Anti-Integrin Antibodies, Compositions, Methods and Uses |
| 07/30/2009 | DE202008010830U1 Arzneimittel und Nahrungsergänzungsmittel mit einem Gehalt an stabilisiertem Ubichinol in einer Schutzverpackung Medicines and dietary supplements containing stabilized ubiquinol in protective packaging |
| 07/30/2009 | DE102007057718A1 New heteroaryl-substituted piperidine compounds are protease-activated receptor antagonists useful for the treatment and/or prophylaxis of e.g. cardiovascular diseases, thromboembolic diseases, tumors, stroke, hypertension and asthma |
| 07/30/2009 | CA2749742A1 3-(sulfonyl)pyrazolo[1,5-a]pyrimidines - antagonists of serotonin 5-ht6 receptors, methods for their preparation and use |
| 07/30/2009 | CA2712791A1 Fused pyridines active as inhibitors of c-met |
| 07/30/2009 | CA2712619A1 Dihydropyridine calcium antagonist compounds, preparation methods and medical uses thereof |
| 07/30/2009 | CA2712222A1 Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use |
| 07/30/2009 | CA2712078A1 Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor |
| 07/29/2009 | EP2083011A1 Pyrroline derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof |
| 07/29/2009 | EP2082743A2 Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes |
| 07/29/2009 | EP2081964A2 Alginate and alginate lyase compositions and methods of use |
| 07/29/2009 | EP2081932A2 2-o'-methyladenosine derivatives and their use as agonists or antagonists of an adenosine receptor |
| 07/29/2009 | EP2081927A1 Piperidine derivatives as renin inhibitors |
| 07/29/2009 | EP2081903A2 2-aminocarbonyl-pyridine derivatives |
| 07/29/2009 | EP2081898A2 Adamantylurea compounds as soluble epoxide hydrolase inhibitors |
| 07/29/2009 | EP2081600A1 Combination of nmda- receptor ligand and a compound with 5-ht6 receptor affinity |
| 07/29/2009 | EP2081572A1 Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group |
| 07/29/2009 | EP1807407B1 Aromatic amides as inhibitors of c-fms kinase |
| 07/29/2009 | EP1686119B1 Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors |
| 07/29/2009 | EP1656154B1 Pharmaceutical composition comprising plant material of trichilia sp. alone or in association with other plant extracts for the reversion/combat and/or prevention of ventricular fibrilation |
| 07/29/2009 | EP1641791B1 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them |
| 07/29/2009 | EP1461025A4 Treatment of neurodegenerative and cardiovascular disorders |
| 07/29/2009 | EP1411895B2 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine |
| 07/29/2009 | EP1406608B1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| 07/29/2009 | EP1397357B1 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 07/29/2009 | EP1363876B1 Glucocorticoid receptor modulators |
| 07/29/2009 | EP1261601B1 Substituted indoles for modulating nfkb activity |
| 07/29/2009 | CN101491670A Method for treating cardiovascular disease using nervous regulation protein and composite |
| 07/29/2009 | CN100519749C Agonist anti-TRK-C monoclonal antibodies |
| 07/29/2009 | CN100519552C Pyrazole compounds |
| 07/29/2009 | CN100519550C 2-oxo-indole compound having a functtion of inhibiting glycogen synthase kinase-3 |
| 07/29/2009 | CN100519549C Pyrimidine derivatives and pharmaceutical compositions containing the compounds |
| 07/29/2009 | CN100519539C N3 alkylated benzimidazole derivatives as MEK inhibitors |
| 07/29/2009 | CN100519527C Inhibitors of histone deacetylase |
| 07/29/2009 | CN100518820C A Pharmaceutical formulation containing an inhibitor of carboxypeptidase U and a thrombin inhibitor |
| 07/29/2009 | CN100518802C Extraction of effective parts for Danshen root and rhizoma chuanxiong |
| 07/29/2009 | CN100518737C Cilostazol solid agent |
| 07/29/2009 | CN100518735C Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 07/29/2009 | CN100518726C Pharmaceutical solutions of modafinil compounds |
| 07/28/2009 | US7566781 melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide |
| 07/28/2009 | US7566778 Central nervous system disorders; psychological disorders |
| 07/28/2009 | US7566770 Humanized collagen antibodies and related methods |
| 07/28/2009 | US7566737 antioxidants and PPAR activators; with rosiglitazone, irbesartan, ezetimibe, simvastatin, Fenofibrate; inflammation, neurodegeneration, cell proliferation; restenosis, atherosclerosis, type 2 diabetes, obesity, hypertension; 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one |
| 07/28/2009 | US7566734 Imidazolyl derivatives |
| 07/28/2009 | US7566723 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use |
| 07/28/2009 | US7566720 9-[2-(1H-indol-3-yl)ethyl]-2-pyridin-4-yl-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one; glycogen synthase kinase 3 beta inhibitors; nerve growth factors; neurodegenerative diseases; Alzheimer's disease; Parkinson's disease; tauopathies; stroke; vision defects;antidiabetic agent; anticarcinogenic |
| 07/28/2009 | US7566717 Substituted heterocyclic compounds |
| 07/28/2009 | US7566699 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof |
| 07/28/2009 | US7566698 Extracted from plants such as Ningxia Lycium barbarum L. and/or Lycium chinense Mill; glucosyltransferases, cellulases; provitamin C with improved stability and bioavailability; ultraviolet damage protector; antiwrinkling; whitening |
| 07/28/2009 | US7566695 Multimeric apoprotein agonists |
| 07/28/2009 | US7566694 Anti-pathogen treatments |
| 07/28/2009 | US7566566 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins |
| 07/28/2009 | US7566539 Anti-CCR2 antibodies and methods of use therefor |
| 07/28/2009 | US7566450 Using cc-chemokine receptor 2 (CCR2) specific immunoglobulins for use in treatment and prevention of skin disorders |
| 07/28/2009 | US7566449 Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins |
| 07/28/2009 | CA2354574C Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same |
| 07/23/2009 | WO2009091898A2 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| 07/23/2009 | WO2009091542A2 Antibodies to bufadienolides prevent inhbition of na/katpase and prolong survival in shock |
| 07/23/2009 | WO2009091341A1 Novel peptides and protein and uses thereof |
| 07/23/2009 | WO2009090933A1 Virus growing in hypoxic cell or virus vector expressing gene therein |
| 07/23/2009 | WO2009090158A1 Atorvastatin-aliskiren |
| 07/23/2009 | WO2009089975A1 Food composition |
| 07/23/2009 | WO2009089680A1 Method of modulating membrane potential of a cell |
| 07/23/2009 | WO2009071690A3 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases |
| 07/23/2009 | WO2009071689A3 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases |
| 07/23/2009 | WO2009065130A3 Modified release formulations of diltiazem |
| 07/23/2009 | WO2009061889A3 Grape polyphenolics for platelet and bacterial control |
| 07/23/2009 | WO2009046845A3 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 07/23/2009 | WO2009043747A3 N-heterocyclic biaryl carboxamides as ccr receptor antagonists |
| 07/23/2009 | WO2009043523A3 Cortistatin 17 and neuropeptide 1 for use as therapeutic agent |
| 07/23/2009 | WO2009040084A3 Use of a peptide as a therapeutic agent |
| 07/23/2009 | WO2009040034A3 Use of a peptide as a therapeutic agent |
| 07/23/2009 | WO2009039973A3 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 07/23/2009 | WO2009033816A3 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 07/23/2009 | WO2009033773A3 Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent |
| 07/23/2009 | WO2009033761A3 Use of a fragment of hcv nucleo protein, alone or together with endothelin-3, as a therapeutic agent |
| 07/23/2009 | WO2009031023A3 Pomegranate extracts, nutritional products containing them and their uses |
| 07/23/2009 | WO2009000843A3 Treatment of heart failure in non-human animal mammals by an aldosterone antagonist |
| 07/23/2009 | WO2008156550A3 Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine |
| 07/23/2009 | WO2008127591A3 Pyrimidinedione derivatives and use thereof |
| 07/23/2009 | WO2008125279A3 Atrial-radiofrequency catheter ablation mediated targeting of mesenchymal stromal cells |
| 07/23/2009 | WO2008084504A3 Pharmaceutical compositions of angiotensin ii receptor blockers |
| 07/23/2009 | WO2008076427A3 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| 07/23/2009 | WO2007094027A8 Methods for the diagnosis of proliferative and/or conformational diseases |
| 07/23/2009 | US20090187013 Synthetic heparin pentasaccharides |
| 07/23/2009 | US20090186921 Azacyclic compounds |
| 07/23/2009 | US20090186914 Ethyl (2S)-2-[(4,4-dimethyl-3-oxo-1-cyclobutenyl)amino]-3-[(4-([2,7]naphthyridin-1-yloxy)phenyl]propanoate; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders |
| 07/23/2009 | US20090186895 Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| 07/23/2009 | US20090186884 such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders |